Brief: OSE Immunotherapeutics Confirms BI 765063 Positive Results

Ose Immunotherapeutics SA

09/03/2022 06:45

March 9 (Reuters) - OSE Immunotherapeutics SA  OSE.PA :
    * EARLY BIOMARKER ANALYSES FROM ONGOING PHASE 1 CLINICAL
TRIAL
WITH SIRPΑ INHIBITOR BI 765063 IN PATIENTS WITH ADVANCED SOLID
TUMORS HAVE BEEN SELECTED FOR PRESENTATION
    * NEW DATA CONFIRM PRECLINICAL RESULTS SHOWING THAT T
LYMPHOCYTES
INITIALLY BLOCKED AT TUMOR'S MARGIN COULD PENETRATE EFFICIENTLY
INTO TUMOR WHEN BLOCKING SIRPΑ IN PARALLEL
    * CROSSING THIS BARRIER IS ASSOCIATED WITH POSITIVE
MODULATION OF
MACROPHAGE EXPRESSION AND SECRETION OF CHEMOKINES ALLOWING
PENETRATION OF T LYMPHOCYTES INTO HEART OF TUMOR

Source text for Eikon:  urn:newsml:reuters.com:*:nGNX90Rvjd
Further company coverage:  OSE.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 772 09 20;))